JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425
JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.
Read original at benzingaStocks · News reference
-Conference Call
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.
Read original at benzingaCNBC's Jim Cramer offers his takes on various companies, including CME Group, Alcoa, Rocket Lab, Fortinet, HCA Healthcare and Hubbell.
Read original at benzingaLaw firm Bragar Eagel & Squire is investigating HCA Healthcare for potential federal securities law violations following the company's July 14, 2026 announcement of sharply lowered full-year profit guidance due to unfavorable payer mix changes impacting revenue by approximately $400 million. HCA's stock fell 6.95% ($27.14 per share) to $363.60 on the news. The firm is seeking stockholders who suffered losses to participate in the action.
Read original at globenewswire-incThe Frist Art Museum in Nashville is presenting 'Shimmer: Dreaming the Posthuman,' an exhibition featuring 17 contemporary artists exploring humanity's interconnectedness with nature and other species through analog and digital technologies. Running from September 25, 2026 through January 3, 2027, the exhibition uses CGI, virtual reality, and other emerging technologies to visualize posthuman perspectives on environmental crises, species extinction, and ecological relationships.
Read original at globenewswire-inc